Fig. 2: Efficacy outcomes in Asian patients according to line of therapy in the combined biopsy group (TBx and/or LBx detection of METex14 skipping). | British Journal of Cancer

Fig. 2: Efficacy outcomes in Asian patients according to line of therapy in the combined biopsy group (TBx and/or LBx detection of METex14 skipping).

From: Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION

Fig. 2

a Tumor response by independent review. b DOR by independent review. c PFS by independent review. d OS. *One patient is not shown due to baseline/on-treatment measurements not being available. †Two patients are not shown due to baseline/on-treatment measurements not being available. 1L first line, 2L+ second or later line, CI confidence interval, DOR duration of response, LBx liquid biopsy, METex14 MET exon 14, NE not evaluable, ne not estimable, OS overall survival, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease, TBx tissue biopsy.

Back to article page